about
A systematic screen of FDA-approved drugs for inhibitors of biological threat agentsDrug repositioning approaches for the discovery of new therapeutics for Alzheimer's diseaseCell-Based Assay Design for High-Content Screening of Drug CandidatesComputational drug repositioning: from data to therapeutics.Integrating Clinical Phenotype and Gene Expression Data to Prioritize Novel Drug UsesDiscovery and preclinical validation of drug indications using compendia of public gene expression data.Exploiting drug-disease relationships for computational drug repositioning.Identification association of drug-disease by using functional gene module for breast cancer.The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors.Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections.Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo.Candidate cancer-targeting agents identified by expression-profiling arrays.Old friends in new guise: repositioning of known drugs with structural bioinformatics.Network-based drug repositioning.Drug target central.Contributions from emerging transcriptomics technologies and computational strategies for drug discovery.The Simultaneous Inhibitory Effect of Niclosamide on RANKL-Induced Osteoclast Formation and Osteoblast DifferentiationIntegration of phytochemicals and phytotherapy into cancer precision medicine.Repurposing an old drug for a new use: glybenclamide exerts antiplatelet activity by interacting with the thromboxane A(2) receptor.The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies.Cardiac glycosides correct aberrant splicing of IKBKAP-encoded mRNA in familial dysautonomia derived cells by suppressing expression of SRSF3.Scoring multiple features to predict drug disease associations using information fusion and aggregation.Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections.
P2860
Q21559667-BD566799-FE80-459E-B3AD-7F11E935BD3FQ27024122-C36AB31D-11A9-46F2-80B2-4789EB96C0B3Q28084264-1BD71567-A627-4021-9665-9D98BA74F2E5Q30594820-FC2121BE-8CBE-489F-927B-64BBBDE170E7Q31143112-D859F143-77DE-40C9-8343-583F4FD30861Q33995422-BF043DB8-E0E3-45E9-B5E4-E3FE3A0CD313Q35109885-7D2BCDA4-F7F6-46FA-9BBB-1B2944A0BE1DQ35653257-58BA75CD-973E-4B9D-874E-A60475CF2058Q35741522-DE8A86FA-931D-48B9-B118-28BB82287B14Q36500235-D097864D-B219-41C1-97A8-74299BFC2E55Q36516568-633BE8B9-DA65-44C5-AD27-1380AE5AEA84Q36802115-8AB6CD1A-11F8-4742-9272-C716FA111170Q37858324-22CD5AB8-BB4F-416D-8B27-2EEC68EBEE4CQ38089597-5CA95454-8EFC-439F-B3B1-05ACF8C0C645Q38089909-E12F93A6-458E-4B0E-9935-8861F01E0F35Q38196339-D8479464-81A2-407A-A794-E5469ACA3B3FQ38694527-920614C5-D92D-4698-82C1-F76785726AD1Q38780465-FBA0E2A7-F142-486E-9F9F-98B098B01686Q39019862-751F691B-6615-4D58-95B0-806C396EBEB4Q39029383-00342E7B-AA4F-4876-8CFA-EAC7ECB5B570Q39147059-6B49AA75-F247-44C0-9994-09494EE859AAQ39562940-F5957766-932B-47F9-AECE-0901816EEEF1Q54289313-8B8C68F3-1131-4269-A50D-EEB71D208834
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Old drugs--new uses
@ast
Old drugs--new uses
@en
Old drugs--new uses
@nl
type
label
Old drugs--new uses
@ast
Old drugs--new uses
@en
Old drugs--new uses
@nl
prefLabel
Old drugs--new uses
@ast
Old drugs--new uses
@en
Old drugs--new uses
@nl
P2860
P1476
Old drugs--new uses
@en
P2093
J K Aronson
P2860
P356
10.1111/J.1365-2125.2007.03058.X
P407
P577
2007-11-01T00:00:00Z